DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
The committee will discuss biologics license application (BLA) 761143, teprotumumab solution for intravenous use, submitted by Horizon Pharma Ireland, Ltd., proposed for the treatment of active thyroid eye disease.
The public participation information has been changed for the December 13, 2019 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee. The deadline for making formal oral presentation requests has been changed from Tuesday, November 26, 2019 to Monday, December 2, 2019. The deadline for submitting electronic or written comments to be provided to the committee has been changed from Wednesday, December 4, 2019 to Monday, December 9, 2019.
Date & Time:
December 13, 2019
8:00 AM to 4:00 PM
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center
The Great Room (Rm. 1503)
Silver Spring, Maryland, United States
This event has ended.
Evidence & EducationHipertiroidismo¿Qué Es El Hipertiroidismo? El térmi...
Evidence & EducationClinical Implications of Immunoglobulin G4 to Graves’ OphthalmopathyBackground: This study aimed to explore...
Evidence & EducationRisk Factors For Developing Thyroid-Associated Ophthalmopathy Among Individuals with Graves’ DiseaseImportance: Thyroid-associated ophthalm...
Evidence & EducationUnderstanding Thyroid Eye DiseaseThyroid eye disease causes the muscles a...
News & MeetingsBreakthrough Treatment for Thyroid Eye DiseaseFor those with severe inflammation from ...
News & MeetingsThyroid Eye Disease Drug Meets Primary Endpoint for Proptosis ReductionTop-line results from the OPTIC trial sh...
Evidence & EducationPediatric Graves’ Disease: Controversies in ManagementBackground/Aims: Graves' disease (GD) i...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.